Foghorn Therapeutics Inc.
NGM: FHTXLive Quote
About Foghorn Therapeutics Inc.
Healthcare
Biotechnology
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
📊 Fundamental Analysis
Foghorn Therapeutics Inc. demonstrates a profit margin of -240.3%, which is below the sector average, suggesting competitive pressure.
The company recently reported 223.8% revenue growth, which is well above average for the Healthcare sector.
At a current price of $4.59, FHTX currently sits at the 36th percentile of its 52-week range (Range: $3.26 - $6.95).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$227.22M
Trailing P/E
--
Forward P/E
-5.04
Beta (5Y)
3.11
52W High
$6.95
52W Low
$3.26
Avg Volume
169K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App